Evidence map›Paper›PMID 40586856›Full record

ArticleJournal of cellular and molecular medicine2025

Thyroid Hormone Dynamics and DIO2 Variants in Schizophrenia: Exploring Genetic Links to Neuroendocrine Imbalance.

Gokce Akan, Ismael Chatita Adolf, Adil Colak, Seda Acar, Fatih Oncu, Dogan Yesilbursa, Solmaz Turkcan, Fatmahan Atalar, Sema Bilgic Gazioglu

Abstract read
In one paragraph

Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gokce AkanBiochemistry Department, MUHAS Genetics Laboratory, School of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.ORCID 0000-0002-3878-1135
Ismael Chatita AdolfBiochemistry Department, MUHAS Genetics Laboratory, School of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Adil ColakDepartment of Biomedical Engineering, Biomedical Engineering Institute, Bogazici University, Istanbul, Türkiye.
Seda AcarDepartment of Bioengineering, Yildiz Technical University, Istanbul, Türkiye.
Fatih OncuPsychiatry Clinics, Turkish Ministry of Health Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Türkiye.
Dogan YesilbursaPsychiatry Clinics, Turkish Ministry of Health Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Türkiye.
Solmaz TurkcanPsychiatry Clinics, Turkish Ministry of Health Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Türkiye.
Fatmahan AtalarBiochemistry Department, MUHAS Genetics Laboratory, School of Medicine, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania.
Sema Bilgic GaziogluDepartment of Immunology, Institute of Experimental Medicine, Istanbul University, Istanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thyroid hormone modulates multiple neurotransmitter systems, including dopaminergic, serotonergic, glutamatergic and GABAergic pathways, which are implicated in schizophrenia (SCH) pathophysiology. The Type II deiodinase (DIO2) enzyme plays a critical role in thyroid metabolism, converting thyroxine (T4) into the biologically active triiodothyronine (T3). This study aimed to investigate the potential association between DIO2 gene polymorphisms, Thr92Ala and ORFa-Gly3Asp, with serum levels of free triiodothyronine (fT3), free thyroxine (fT4) and thyroid-stimulating hormone (TSH) in SCH susceptibility and symptomatology. The cohort included 582 unrelated patients diagnosed with SCH and 603 healthy controls. Genotyping of Thr92Ala and ORFa-Gly3Asp single nucleotide polymorphisms (SNPs) of the DIO2 gene was conducted along with serum measurements of TSH, fT4 and fT3 levels. The genotype distribution of Thr92Ala and ORFa-Gly3Asp genotypes differed significantly between SCH group and the controls (p < 0.001). Furthermore, patients with SCH exhibited significantly lower levels of fT3 (p < 0.001) and TSH (p < 0.001) compared with controls. Notably, the Thr92Ala genotypes displayed a significant association with altered fT3 and TSH levels in SCH patients (p < 0.05, respectively). This study identified a significant association between DIO2 polymorphisms and decreased levels of fT3 and TSH in Turkish patients with SCH. Given the impact of thyroid hormones on neurotransmitter systems involved in SCH, these results highlight the potential for thyroid hormone modulation as a therapeutic avenue. Further research could lead to more personalised treatment strategies, particularly for patients with genetic predispositions to altered thyroid hormone metabolism, improving clinical outcomes and offering new approaches to managing symptoms in schizophrenia.

Indexed as

Iodide PeroxidaseNeurosecretory SystemsPolymorphism, Single NucleotideSchizophreniaThyroid HormonesAdultCase-Control StudiesFemaleGenetic Predisposition to DiseaseGenotypeHumansIodothyronine Deiodinase Type IIMaleMiddle AgedThyrotropinThyroxineIodide PeroxidaseIodothyronine Deiodinase Type IIThyroid HormonesThyrotropinThyroxineTriiodothyroninecase‐control studydeiodinase enzyme IIDIO2genotypingpolymorphismschizophreniathyroid hormone

Identifiers

PMID40586856
PMCPMC12207988

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.